Michael Goltzman, MD
Urology · Danbury, CTNPI 1326570722
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,502 of the $9,617 with a category attached, or 67.6%. It is spread thinly across 42 manufacturers, the largest accounting for just 16.4%.
Across 239 payments — averaging $40.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Histosonics, Inc.$1K
- Johnson & Johnson$778
- Sumitomo Pharma America, Inc.$713
- Coloplast$707
- Teleflex LLC$639
- plus $4K from 36 others
What the payments were for
- Consulting fees$1,50016%
- Travel & lodging$1,57416%
- Food & beverage$6,50268%
- Education$400%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 4 | $1,577 |
| Histosonics, Inc. | 2 | $1,164 |
| Johnson & Johnson | 28 | $778 |
| Sumitomo Pharma America, Inc. | 32 | $713 |
| Coloplast | 4 | $707 |
| Teleflex LLC | 16 | $639 |
| Bayer | 19 | $516 |
| Pfizer | 16 | $376 |
| Merck | 10 | $349 |
| Progenics Pharmaceuticals, Inc. | 9 | $269 |
| Astellas Pharma US Inc | 10 | $226 |
| Axonics, Inc. | 4 | $224 |
| Accord Healthcare, Inc. | 10 | $223 |
| Procept Biorobotics Corporation | 2 | $212 |
| Urogen Pharma, Inc. | 9 | $199 |
| Ferring Pharmaceuticals Inc. | 8 | $169 |
| Endo USA, Inc. | 6 | $148 |
| Innovation Technologies Inc | 1 | $114 |
| AbbVie | 5 | $114 |
| Agiliti Surgical, Inc. | 5 | $103 |
| Urovant Sciences Inc | 5 | $98 |
| Myriad Genetic Laboratories, Inc. | 4 | $85 |
| Novartis | 4 | $85 |
| Tolmar, Inc. | 3 | $68 |
| Myovant Sciences Inc. | 2 | $51 |
| Sun Pharmaceutical Industries Inc. | 2 | $51 |
| Endo Pharmaceuticals Inc. | 2 | $35 |
| Tolmar Pharmaceuticals, Inc. | 2 | $35 |
| Vertex | 2 | $31 |
| Telix Pharmaceuticals | 1 | $26 |
| Conmed Corporation | 1 | $25 |
| Mission Pharmacal Company | 1 | $23 |
| Photocure Inc | 1 | $21 |
| Medtronic | 1 | $20 |
| BD | 1 | $20 |
| Olympus America Inc. | 1 | $20 |
| Laborie Medical Technologies Corp. | 1 | $19 |
| Palette Life Sciences, Inc. | 1 | $18 |
| Calyxo, Inc. | 1 | $17 |
| Immunitybio, Inc. | 1 | $16 |
| Profound Medical Corp. | 1 | $16 |
| Angiodynamics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- rezum Generator$1,500
- TITAN$667
- AQUABEAM SYSTEM$192
- UroLift$159
- Axonics$148
- KEYTRUDA$125
- Irrisept$114
How this compares
$9,617 in reported general payments places this provider in the 80th percentile of 156 urology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 33 | $482,872 |
| OrgovyxRelugolix | 100 | $271,028 |
| ErleadaApalutamide | 13 | $194,395 |
| NubeqaDarolutamide | 12 | $167,068 |
| MyrbetriqMirabegron | 93 | $83,007 |
| GemtesaVibegron | 108 | $78,917 |
| Mirabegron ErMirabegron | 12 | $6,125 |
| Tamsulosin Hcl | 418 | $5,252 |
| Tolterodine Tartrate | 63 | $4,190 |
| Finasteride | 126 | $1,394 |
| Methenamine Hippurate | 26 | $1,300 |
| Oxybutynin Chloride ErOxybutynin Chloride | 70 | $1,265 |
| Potassium Citrate ErPotassium Citrate | 14 | $1,165 |
| Estradiol | 28 | $1,027 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 36 | $1,006 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $226 | $565,879126 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $713 | $349,945208 claims |
| Johnson & JohnsonErleada | $778 | $194,39513 claims |
| BayerNubeqa | $516 | $167,06812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 156 urology providers in Connecticut.
Other urology in Danbury
- John BrunoDanbury$9K
- Stanford BroderDanbury$8K
- Alex HennesseyDanbury$6K
- Jeffrey GorelickDanbury$5K
- Edward BeckDanbury$5K
- Daniel KellnerNew Haven$122K
- Gerard PregenzerEnfield$92K
- Mary SoysterTorrington$58K
- Preston SprenkleNew Haven$57K
- Grace BiggsDerby$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.